Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects.
about
Increased sensitivity to thermal pain following a single opiate dose is influenced by the COMT val(158)met polymorphismTolerance and withdrawal from prolonged opioid use in critically ill children.Opioid rotation in clinical practice.Genetic contributions to clinical pain and analgesia: avoiding pitfalls in genetic researchRecent advances in the use of opioids for cancer painA clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk.Pharmacogenetics of analgesic drugsGenetic and Non-genetic Factors Associated With Constipation in Cancer Patients Receiving Opioids.Analgesia and central side-effects: two separate dimensions of morphine response.Pharmacogenetics of chronic pain and its treatment.Genetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with painVariation in the COMT gene: implications for pain perception and pain treatment.Migraine pain: reflections against vasodilatation.Personalized therapy in pain management: where do we stand?Pain, analgesia and genetics.Opioid genetics: the key to personalized pain control?Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.Association Between Human Pain-Related Genotypes and Variability in Opioid Analgesia: An Updated Review.Clinical Implications of Opioid Pharmacogenomics in Patients With Cancer.Pharmacogenomics and Patient Treatment Parameters to Opioid Treatment in Chronic Pain: A Focus on Morphine, Oxycodone, Tramadol, and Fentanyl.Acute kidney injury in a preterm infant homozygous for the C3435T polymorphism in the ABCB1 gene given oral morphine.The genetic influences on oxycodone response characteristics in human experimental pain.Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids.Pain management with morphine: variation in analgesic response secondary to genetic polymorphisms.Relationship Between ABCB1 Polymorphisms and Cold Pain Sensitivity Among Healthy Opioid-naive Malay Males.An exploratory analysis on the effectiveness of four strong opioids in patients with cancer pain.Prevalence of dysphoria after fentanyl in dogs undergoing stifle surgery.Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg.Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers.Is there a role for pharmacogenetics in the dosing of fentanyl?Catechol-O-methyltransferase genotype (Val158met) modulates cancer-related fatigue and pain sensitivity in breast cancer survivors.Comparison of analgesic effect of oxycodone and morphine on patients with moderate and advanced cancer pain: a meta-analysis
P2860
Q28475633-3FE79A09-1A87-44B0-BBB7-92F4E859CF55Q30428413-2CF68C97-471D-4DE2-86D3-17E216B192E9Q34305249-451CD861-9611-480B-8A55-F3AFD7587E02Q34391905-29307E4D-C999-49C7-9CFD-80EBAB48183DQ34418203-429EB64A-2F08-4AAD-B294-48519F3414A2Q34905699-01E1612A-C0D3-47D2-BB3D-46E1812A6F23Q36110592-5AB32332-7547-4F1A-B75D-78AB110D05A7Q36751995-94733B27-79EE-440E-8C3D-E8BCF8DCB5E9Q36792999-355F005B-E048-4D40-90E5-F260573FC91EQ36900075-0387C651-C00A-48DC-AC45-1464999FD31DQ37102220-FF3B64A9-CABF-4717-9722-6BC81FAE4B53Q37448922-64C77D98-F9A8-4415-87C4-78704A1A9FF3Q37508771-F8A6D2FA-A364-4338-ADA6-36D5C3586BA7Q37760955-78E66EFC-3491-4876-9939-324FBA8FBBFDQ37944353-62214C29-6B93-47DF-AD4C-1A9355CE7DC5Q38025200-7B06C7F9-D823-41FB-90B9-FA5629884E39Q38243832-703B2BAC-DD65-45F8-88D8-6C6851B33568Q38247246-886F3569-2DAD-4D4A-B894-955EF2643B6FQ38672362-9217963F-CCE2-433B-AE4A-E76B6F9EDBE1Q39198915-E9158F3C-0D8B-44B4-BF89-831404895FD6Q40684580-F92C97DB-8C8B-4574-8CC9-DB4A73B79F10Q40870241-E80FF5B3-0B6D-4C83-B4D9-9FE554FCAF17Q40873003-573F5430-7E3C-4B3B-A788-4BF98B5843E2Q42198604-71B92A17-106F-43FC-9550-79665260BD74Q44342118-4719B38A-88EA-4292-8FCE-73918EE36D4DQ45832293-10F12B6D-B04C-42B9-959C-9107E957C39FQ48107989-957B4489-74BB-4E6F-8F8B-19A4C5FB023EQ48490118-A626B896-F6C5-41FB-A6C4-C8A58152BAC1Q48717168-7BF89783-4BF9-4E60-87CE-3AA4F36E5CB9Q53682973-897652A9-C8D4-4A93-BC89-6AEA7F59265BQ54350345-6325E843-F6FB-4AA3-B3AF-8264303FAC2EQ58701016-F64E5C2C-1FAC-4433-B1D3-55F79D3D52A4
P2860
Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Genetic variation and response ...... ted with central side effects.
@ast
Genetic variation and response ...... ted with central side effects.
@en
Genetic variation and response ...... ted with central side effects.
@nl
type
label
Genetic variation and response ...... ted with central side effects.
@ast
Genetic variation and response ...... ted with central side effects.
@en
Genetic variation and response ...... ted with central side effects.
@nl
prefLabel
Genetic variation and response ...... ted with central side effects.
@ast
Genetic variation and response ...... ted with central side effects.
@en
Genetic variation and response ...... ted with central side effects.
@nl
P2093
P356
P1433
P1476
Genetic variation and response ...... ted with central side effects.
@en
P2093
Annie B Taegetmeyer
Hiroe Sato
Joy R Ross
Julia Riley
Kenneth I Welsh
Roland M du Bois
Sophy Gretton
P304
P356
10.1002/CNCR.23292
P407
P577
2008-03-01T00:00:00Z